Rafael Holdings, Inc. Class B (RFL): Price and Financial Metrics


Rafael Holdings, Inc. Class B (RFL)

Today's Latest Price: $16.09 USD

0.09 (0.56%)

Updated Sep 25 7:00pm

Add RFL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RFL Stock Summary

  • The ratio of debt to operating expenses for Rafael Holdings Inc is higher than it is for about merely 0.34% of US stocks.
  • With a price/sales ratio of 50.18, Rafael Holdings Inc has a higher such ratio than 95.87% of stocks in our set.
  • With a year-over-year growth in debt of -100%, Rafael Holdings Inc's debt growth rate surpasses only 0% of about US stocks.
  • Stocks that are quantitatively similar to RFL, based on their financial statements, market capitalization, and price volatility, are ROG, OFIX, SILK, CUB, and ISDR.
  • RFL's SEC filings can be seen here. And to visit Rafael Holdings Inc's official web site, go to www.rafaelholdings.com.
RFL Daily Price Range
RFL 52-Week Price Range

RFL Stock Price Chart Technical Analysis Charts


RFL Price/Volume Stats

Current price $16.09 52-week high $23.76
Prev. close $16.00 52-week low $9.40
Day low $15.54 Volume 8,720
Day high $16.60 Avg. volume 32,954
50-day MA $16.33 Dividend yield N/A
200-day MA $16.02 Market Cap 254.50M

Rafael Holdings, Inc. Class B (RFL) Company Bio


Rafael Holdings, Inc., through its subsidiary, manufactures metabolic oncology drugs to treat cancer. The company also owns and operates real estate properties. The company was incorporated in 2017 and is based in Newark, New Jersey. Rafael Holdings, Inc. operates as a subsidiary of IDT Corporation


RFL Latest News Stream


Event/Time News Detail
Loading, please wait...

RFL Latest Social Stream


Loading social stream, please wait...

View Full RFL Social Stream

Latest RFL News From Around the Web

Below are the latest news stories about Rafael Holdings Inc that investors may wish to consider to help them evaluate RFL as an investment opportunity.

LD Micro - 360 Companies Set to Present - this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Yahoo | August 31, 2020

Would Shareholders Who Purchased Rafael Holdings'(NYSE:RFL) Stock Year Be Happy With The Share price Today?

Rafael Holdings, Inc. (NYSE:RFL) shareholders should be happy to see the share price up 11% in the last month. But...

Yahoo | August 26, 2020

Rafael Holdings to Present at LD Micro Investor Conference

Rafael Holdings, Inc., (NYSE: RFL), today announced that it will present at The LD 500 Virtual Conference on Thursday, September 3, 2020.

Yahoo | August 24, 2020

Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

One of the largest active Phase 3 clinical trials in metastatic pancreatic cancer, completes target enrollment ahead of scheduleCRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has reached its target enrollment of 500 patients in its pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of Rafael’s lead compound CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy. The global study will remain open for a short while longer and continue to enroll additional patients.  “The speed at which we were able to fully enroll the Phase 3 tr...

Yahoo | August 6, 2020

Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cranbury, NJ, July 21, 2020 -- Rafafel_Pharma_PHP_Graphic_Updated_V3 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer.

Yahoo | July 21, 2020

Read More 'RFL' Stories Here

RFL Price Returns

1-mo -4.23%
3-mo 9.98%
6-mo 25.60%
1-year -17.61%
3-year N/A
5-year N/A
YTD -9.81%
2019 124.97%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching RFL

Want to see what other sources are saying about Rafael Holdings Inc's financials and stock price? Try the links below:

Rafael Holdings Inc (RFL) Stock Price | Nasdaq
Rafael Holdings Inc (RFL) Stock Quote, History and News - Yahoo Finance
Rafael Holdings Inc (RFL) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8142 seconds.